| Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial DA Palma, R Olson, S Harrow, RJM Correa, F Schneiders, CJA Haasbeek, ... BMC cancer 19, 1-15, 2019 | 214 | 2019 |
| Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection FL Schneiders, RJ Scheper, BME von Blomberg, AM Woltman, ... Clinical immunology 140 (2), 130-141, 2011 | 116 | 2011 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial R Olson, L Mathews, M Liu, D Schellenberg, B Mou, T Berrang, S Harrow, ... BMC cancer 20, 1-12, 2020 | 97 | 2020 |
| Bispecific antibody platforms for cancer immunotherapy R Lameris, RCG de Bruin, FL Schneiders, PMPB en Henegouwen, ... Critical reviews in oncology/hematology 92 (3), 153-165, 2014 | 92 | 2014 |
| A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells RCG de Bruin, JP Veluchamy, SM Lougheed, FL Schneiders, ... Oncoimmunology 7 (1), e1375641, 2018 | 87 | 2018 |
| Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up FL Schneiders, RC De Bruin, AJ Van Den Eertwegh, RJ Scheper, ... J Clin Oncol 30 (5), 567-70, 2012 | 74 | 2012 |
| Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells … BJR Sluijter, MFCM van den Hout, BD Koster, PAM van Leeuwen, ... Cancer immunology research 3 (5), 495-505, 2015 | 69 | 2015 |
| Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review EB Ulas, C Dickhoff, FL Schneiders, S Senan, I Bahce Esmo Open 6 (5), 100244, 2021 | 59 | 2021 |
| Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α FL Schneiders, RCG de Bruin, SJAM Santegoets, M Bonneville, E Scotet, ... Clinical Immunology 142 (2), 194-200, 2012 | 30 | 2012 |
| Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial C Dickhoff, S Senan, FL Schneiders, J Veltman, S Hashemi, JMA Daniels, ... BMC cancer 20, 1-10, 2020 | 29 | 2020 |
| CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis FL Schneiders, J Prodöhl, JM Ruben, T O'Toole, RJ Scheper, ... Cancer immunology research 2 (8), 732-740, 2014 | 25 | 2014 |
| mTOR inhibition per se induces nuclear localization of FOXP3 and conversion of invariant NKT (iNKT) cells into immunosuppressive regulatory iNKT cells CM Huijts, FL Schneiders, JJ Garcia-Vallejo, HM Verheul, TD de Gruijl, ... The Journal of Immunology 195 (5), 2038-2045, 2015 | 24 | 2015 |
| Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing Y van Der Pol, NA Tantyo, N Evander, AE Hentschel, BMM Wever, ... EMBO molecular medicine 15 (12), e17282, 2023 | 14 | 2023 |
| 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial I Bahce, C Dickhoff, FL Schneiders, J Veltman, DJ Heineman, S Hashemi, ... Annals of Oncology 33, S982, 2022 | 14 | 2022 |
| Same-day consultation, simulation and lung Stereotactic Ablative Radiotherapy delivery on a Magnetic Resonance-linac MA Palacios, S Verheijen, FL Schneiders, O Bohoudi, BJ Slotman, ... Physics and Imaging in Radiation Oncology 24, 76-81, 2022 | 12 | 2022 |
| Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy H Chen, FL Schneiders, AME Bruynzeel, FJ Lagerwaard, JRS de Koste, ... Radiotherapy and Oncology 163, 14-20, 2021 | 12 | 2021 |
| Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period C van Vliet, C Dickhoff, I Bahce, AF Engelsman, SMS Hashemi, ... Radiotherapy and Oncology 170, 165-168, 2022 | 11 | 2022 |
| Beyond checkpoint inhibitors: enhancing antitumor immune response in lung cancer RE Sanborn, FL Schneiders, S Senan, SM Gadgeel American Society of Clinical Oncology Educational Book 42, 673-686, 2022 | 10 | 2022 |
| Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin FL Schneiders, HP van den Berg, GJ Peters, HMW Verheul, ... Medical oncology 28, 1136-1139, 2011 | 10 | 2011 |
| Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines R Lameris, FL Schneiders, TD de Gruijl, HJ van der Vliet Cancer Vaccines: Methods and Protocols, 155-165, 2014 | 9 | 2014 |
